| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3859 |
| Trial ID | NCT06377228 |
| Disease | Lupus Nephritis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | TAK-007 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-007, an Allogeneic Anti-CD19 Chimeric Antigen Receptor Natural Killer Cell (CD19 CAR-NK) Therapy, in Adult Subjects With Refractory Lupus Nephritis |
| Year | 2024 |
| Country | Japan |
| Company sponsor | Takeda |
| Other ID(s) | TAK-007-1001 |
| Cohort 1 | |||||||||||||
|
|||||||||||||